Company: IMRX
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001790340-25-000014
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-01-13
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

Recent Developments

On January 13, 2025, Immuneering Corporation (the "Company") announced updated interim response and safety data from the ongoing Phase 2a arm evaluating IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients, part of the Company's ongoing Phase 1/2a clinical trial of IMM-1-104 in patients with advanced RAS-mutant solid tumors.

The Company announced that, as of January 6, 2025, of the six evaluable patients in the ongoing Phase 2a arm evaluating IMM-1-104 with mFFX in first-line pancreatic cancer, three patients achieved a partial response (one unconfirmed) and three patients achieved stable disease, collectively representing an interim 50% (3/6) overall response rate (ORR), in each case as measured by RECIST. The three patients that achieved partial responses, and one of the patients that achieved stable disease, remained on treatment. The Company also announced that, as of January 6, 2025, IMM-1-104 in combination with mFFX was observed to be generally well tolerated.

On January 13, 2025, the Company also announced that it raised net proceeds of $13.7 million in January 2025, through utilization of the Company's at-the-market equity offering program.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              IMMUNEERING CORPORATION                                                
  Date: January 13, 2025      By:                          /s/ Michael D. Bookman                    
                                                           Name: Michael D. Bookman                  
                                                           Title: Chief Legal Officer and Secretary